BIOR
NASDAQBiora Therapeutics Inc.
Latest news
25 items- PRBiora Therapeutics Successfully Completes Restructuring ProcessSAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Biora Therapeutics, a biotech company developing the first swallowable autoinjector, today announced the successful completion of its court-supervised restructuring. Through the restructuring process, Biora achieved an improved balance sheet with deleveraged debt and significant new financing to support the business going forward. Biora has emerged from the restructuring as a privately held company. "Emergence marks a new beginning for us as a leaner, stronger, well-capitalized company with a mission to revolutionize the way biologic pharmaceuticals are delivered to patients," said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. "W
- SECBiora Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Financial Statements and Exhibits8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
- PRBiora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future GrowthSale process will help enable next stage of product development Secures up to $10.25 million in new financing to support ongoing business operations SAN DIEGO, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. ("Biora" or the "Company"), a biotech company developing smart pill-based therapeutic platforms, today announced it has reached an agreement with certain of its prepetition creditors (the "Lenders") to provide financing to support a chapter 11 sale process, which will ultimately lead to a strengthened balance sheet and help enable it to launch its next stage of product development. To effectuate the transaction, the Company has filed a voluntary petition under chapter 11 o
- INSIDERSEC Form 4 filed by Director Athyrium Opportunities Iii Co-Invest 1 Lp4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
- SECSEC Form 8-K filed by Biora Therapeutics Inc.8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
- SECSEC Form 8-K filed by Biora Therapeutics Inc.8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
- SECSEC Form 10-Q filed by Biora Therapeutics Inc.10-Q - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
- SECBiora Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
- 13D/GSEC Form SC 13G filed by Biora Therapeutics Inc.SC 13G - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
- PRBiora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsTesting in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any ingestible injectable Company granted extension until December 9 to regain compliance with Nasdaq listing requirements for market value of securities SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today provided a corporate update and reported financial results for the third quarter ended September 30, 2024. The company will not host a conference call. "We've made much faster progress than anticipated developing a smaller BioJet device that is highly desired by pharma companies," said A
- PRBiora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate UpdateSAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the third quarter ended September 30, 2024. Company management will host a webcast and conference call on Thursday, November 14, 2024, after the close of financial markets. Conference Call and Webcast InformationDate: Thursday, November 14, 2024Time: 4:30 PM Eastern time / 1:30 PM Pacific timeConference Call: Domestic 1-877-423-9813International 1-201-689-8573Conference ID 13749254Live Webcast: https://investors.bioratherapeutics.com/events-presentations A replay will
- SECBiora Therapeutics Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
- SECSEC Form 424B5 filed by Biora Therapeutics Inc.424B5 - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
- SECSEC Form 424B3 filed by Biora Therapeutics Inc.424B3 - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
- SECSEC Form 424B3 filed by Biora Therapeutics Inc.424B3 - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
- SECSEC Form 424B3 filed by Biora Therapeutics Inc.424B3 - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
- SECSEC Form 424B3 filed by Biora Therapeutics Inc.424B3 - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
- SECSEC Form 424B3 filed by Biora Therapeutics Inc.424B3 - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
- PRBiora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesSAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced that it has entered into definitive agreements for the purchase and sale of 745,342 shares of the Company's common stock at an offering price of $4.025 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 745,342 shares of common stock. The warrants have an exercise price of $3.90 per share, will be exercisable upon issuance, and will expire five years following issuance. The closing
- PRBiora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD MeetingSAN DIEGO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today is sharing progress on its development of the BioJet™ Oral Delivery Platform, which is designed to replace injection with needle-free, oral delivery, at the 14th Annual Partnership in Drug Delivery (PODD) meeting in Boston, Massachusetts. "We have now demonstrated the ability to autonomously deliver to the small intestine in canine models with our smaller, 00-size BioJet device, a size that is desired by both patients and pharma companies," said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. "We have agreed with existing mega-cap p
- SECSEC Form DEF 14A filed by Biora Therapeutics Inc.DEF 14A - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
- PRBiora Therapeutics to Reveal 00-Size BioJet™ Device at the 14th Annual Partnership Opportunities in Drug Delivery MeetingSAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced that Adi Mohanty, CEO of Biora Therapeutics, will present on the company's 00-size BioJet™ device at the 14th Annual Partnership Opportunities in Drug Delivery (PODD) meeting, taking place in Boston, October 28–29, 2024. "As part of the development of our clinical-ready BioJet device, we were able to reduce its size from 000 to 00, while slightly increasing the payload capacity," said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. "Market research indicates a strong patient preference for a 00-size device, a preference that
- SECSEC Form PRE 14A filed by Biora Therapeutics Inc.PRE 14A - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
- SECBiora Therapeutics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
- 13D/GAmendment: SEC Form SC 13D/A filed by Biora Therapeutics Inc.SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
BIOR FAQ
6 questionsWhat does Biora Therapeutics Inc. do?
Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine...Where does BIOR stock trade?
Biora Therapeutics Inc. (BIOR) is listed on NASDAQ.What sector and industry is BIOR in?
Biora Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Biora Therapeutics Inc. go public?
Biora Therapeutics Inc. (BIOR) completed its IPO in 2020.What companies are similar to BIOR?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare BIOR side-by-side with any of them on Quantisnow.How can I track BIOR on Quantisnow?
Quantisnow aggregates Biora Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BIOR to receive live email and push alerts on every new disclosure.